 Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence. (Stedman, 25th ed)
| Descriptor ID |
D002295
|
| MeSH Number(s) |
C04.557.470.200.430
|
| Concept/Terms |
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in UAMS Profiles by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 2 | 0 | 2 | | 2022 | 4 | 0 | 4 | | 2020 | 3 | 0 | 3 | | 2019 | 3 | 0 | 3 | | 2018 | 3 | 0 | 3 | | 2017 | 2 | 0 | 2 | | 2016 | 1 | 1 | 2 | | 2014 | 2 | 0 | 2 | | 2013 | 1 | 1 | 2 | | 2012 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2010 | 3 | 1 | 4 | | 2009 | 2 | 0 | 2 | | 2006 | 0 | 1 | 1 | | 2005 | 3 | 1 | 4 | | 2004 | 2 | 0 | 2 | | 2003 | 2 | 0 | 2 | | 2002 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles over the past ten years.
-
Matthew-Onabanjo AN, Nortey G, Matulewicz RS, Basak R, Culton DA, Weaver KN, Gallagher KK, Tan HJ, Rose TL, Milowsky M, Bjurlin MA. Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot. Curr Probl Cancer. 2023 06; 47(3):100958.
-
Kirk PS, Lotan Y, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Spiess PE, van Rhijn BWG, Mertens L, Black P, Wright JL. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.
-
Warrick JI, Hu W, Yamashita H, Walter V, Shuman L, Craig JM, Gellert LL, Castro MAA, Robertson AG, Kuo F, Ostrovnaya I, Sarungbam J, Chen YB, Gopalan A, Sirintrapun SJ, Fine SW, Tickoo SK, Kim K, Thomas J, Karan N, Gao SP, Clinton TN, Lenis AT, Chan TA, Chen Z, Rao M, Hollman TJ, Li Y, Socci ND, Chavan S, Viale A, Mohibullah N, Bochner BH, Pietzak EJ, Teo MY, Iyer G, Rosenberg JE, Bajorin DF, Kaag M, Merrill SB, Joshi M, Adam R, Taylor JA, Clark PE, Raman JD, Reuter VE, Chen Y, Funt SA, Solit DB, DeGraff DJ, Al-Ahmadie HA. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nat Commun. 2022 11 02; 13(1):6575.
-
Hogan K, McKenney JK, Cox RM, Nguyen JK, Shah RB, Billings SD, Przybycin CG. Myxoid Pseudotumor Involving the Renal Sinus: Clinicopathologic Study of 33 Cases Supporting a Distinct Benign Non-neoplastic Lesion. Am J Surg Pathol. 2023 02 01; 47(2):218-223.
-
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.
-
Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):453.e19-453.e26.
-
Przybycin CG, McKenney JK, Nguyen JK, Shah RB, Umar SA, Harik L, Shih IM, Cox RM. Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases. Am J Surg Pathol. 2020 10; 44(10):1322-1330.
-
Sangoi AR, Cox RM, Higgins JP, Quick CM, McKenney JK. Non-invasive papillary urothelial carcinoma with 'micropapillary' architecture: clinicopathological study of 18 patients emphasising clinical outcomes. Histopathology. 2020 Nov; 77(5):728-733.
-
Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan; 205(1):100-108.
-
Mannan R, Taylor AS, Spratt DE, Chinnaiyan AM, Montgomery JS, Brown NA, Mehra R. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Pathol Res Pract. 2020 Jan; 216(1):152663.
-
Khalil MI, Alliston JT, Bauer-Erickson JJ, Davis R, Bissada NK, Kamel MH. Organ-sparing procedures in GU cancer: part 3-organ-sparing procedures in urothelial cancer of upper tract, bladder and urethra. Int Urol Nephrol. 2019 Nov; 51(11):1903-1911.
-
Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Nov; 37(11):2419-2427.
-
Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, Palapattu G, Hafez K, Magers MJ, Kaffenberger SD, Spratt DE, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. Hum Pathol. 2019 04; 86:76-84.
-
Cox RM, Magi-Galluzzi C, McKenney JK. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update. Adv Anat Pathol. 2018 Nov; 25(6):387-399.
-
Kamel M, Bhandari NR, Davis R, Payakachat N. Health-related quality of life among elderly Americans diagnosed with upper tract urothelial carcinoma. Urol Oncol. 2018 10; 36(10):469.e13-469.e20.
-
Brown NA, Lew M, Weigelin HC, Weizer AZ, Montgomery JS, Betz BL, Mehra R. Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. Histopathology. 2018 01; 72(2):354-356.
-
Hussain SA, Ansari J, Huddart R, Power DG, Lyons J, Wylie J, Vilarino-Varlela M, Elander NO, McMenemin R, Pickering LM, Faust G, Chauhan S, Jackson RJ. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. Int J Oncol. 2017 Mar; 50(3):768-772.
-
Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, Spratt DE, Jiang H, Mehra R. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2017 10; 3(4-5):502-509.
-
Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|